Index to Volume 299

AUTHORS

Anderson CR (See Clifton GG).
Aronoff GR (See Fried T).
Azzi RL (See Kirsch CM).
Bada HS (See White RP).
Balducci L, Parker M, Hescock, H, Tantranond P, Sexton W. Review: Systemic Management of Prostate Cancer. 299(3):185–192.
Barker PE. Molecular Biology in Medicine: Gene Mapping and Cystic Fibrosis. 299(1):69–72.
Baughman RP (See Lower EE).
Beckmann ML (See Gerber JG).
Belsky M (See Levy JR).
Benabe JE (See Fried T).
Berenson GS, Shear CL, Chiang YK, Webber LS, Voors, AW. Combined Low-Dose Medication and Primary Intervention Over a 30-Month Period for Sustained High Blood Pressure in Childhood. 299(2):79–86.
Borst M, Miller M. Molecular Biology in Medicine: DNA Isolation and Southern Analysis: A Clinician's View. 299(5): 356–360.
Bradshear RW (See McMurray RW).
Brater DC (See Murray MD).
Braverman LE (See De Bruin TWA).
Brown RS (See De Bruin TWA).
Brunner HR (See Fried T).
Byyny RL (See Gerber JG).
Carella MJ, Murray RH, Mendonca-Calaca WDe. Case Report: Diffuse Pulmonary Tumor Microemboli from Prostatic Carcinoma with an Associated Fibrous Histiocytic Sarcoma. 299(2):107–112.
Castro O (See McPherson E).
Chiang YK (See Berenson GS).
Ching DL (See Kim EL).
Cigarroa RG (See Flores ED).
Cliftin GG, Oelsner D, Anderson CR, Pearce CJ, Wallin JD. The Effects of Mercuric Chloride on Calmodulin-Mediated Ca2 Transport in Rat Brain. 299(1):26–31.
Cluette-Brown J (See Doyle K).
Comstock JP (See Ellerhorst JA).
Connelly JE (See Philbrick JT).
Cook DJ. Clinical Assessment of Central Venous Pressure in the Critically Ill. 299(3):175–178.
Cooke CR (See Williams HH).
Corbett EC (See Philbrick JT).
Cuthbert JA. Southwestern Internal Medicine Conference: Hepatitis C. 299(5):346–355.
Dahlöf C, Dimenäs E. Side Effects of β-Blocker Treatments as Related to the Central Nervous System. 299(4):236–244.
De Bruin TWA, Braverman LE, Brown RS. Heterogeneity of TSH Receptor-binding Antibodies in Hashimoto's Thyroiditis and Graves' Disease. 299(5).291–297.
Dessypris EN (See Trochtenberg DS).
DiBona GF (See Fried T).
Diederich DA (See Weigmann TB).
Digirolamo M (See Watts NB).
Dimenäs E (See Dahlöf C).
Doyle K, Hojnacki J, Cluette-Brown J. Ethanol-Induced Alterations in Erythrocyte Membrane Phospholipid Composition. 299(2):98–102.
Duett J (See Jain SK).
Dunnmon PM (See Firth BG).
Ellerhorst JA, Comstock JP, Nell LJ. Protamine Antibody Production in Diabetic Subjects Treated with NPH Insulin. 299(5):298–301.
Fedson DS (See Philbrick JT).
Fincher R-ME, Jackson MW, Fischer AQ. Case Report: *Citrobacter Freundii*: A Newly Reported Cause of Pyomyositis. 299(5):331–333.
Finke H (See McPherson E).
Firth BG, Dunnmon PM. Southwestern Internal Medicine Conference: Prevention of Congestive Heart Failure: Left Ventricular Dilation and its Management. 299(4):276–290.
Fischer AQ (See Fincher R-ME).
Fleischhauer T (See Fried T).
Flores ED, Lange RA, Cigarroa RG, Hillis LD. Southwestern Internal Medicine Conference: Therapy of Acute Myocardial Infarction in the 1990s. 299(6):415–424.
Florsheim W (See Wu S-Y).
Foulis PR (See Greene JN)).
Fried T, Aronoff GR, Benabe JE, Brunner HR, DiBona GF, Fleischhauer T, Lam M, Lawton WJ, Luft FC, Martinez-Maldonado M, McCullough A, Petrillo A. Renal and Hemodynamic Effects of Atrial Natriuretic Peptide in Patients with Cirrhosis. 299(1):2–9.
Fulop M. Hyperkalemia in Diabetic ketoacidosis. 299(3):164–169.
Geppert T. Southwestern Internal Medicine Conference: Clinical Features, Pathogenic Mechanisms, and New Developments in the Treatment of Systemic Sclerosis. 299(3):193–209.
Gerber JG, Beckmann ML, Loverde M, Byyny RL, Nies AS. Hydralazine Does Not Stimulate Prostacyclin Biosynthesis in Hypertensive Patients. 299(3):170–174.
Gordon J (See Greenstein RJ).
Greene JN, Foulis PR, Yangco BG. Case Report: Chromomycosis in a Steroid- Dependent Patient with Chronic Obstructive Pulmonary Disease. 299(1): 54–57.
Greenstein RJ, Isola L, Gordon J. Differential Cholecystokinin Gene Expression in Brain and Gut of the Fasted Rat. 299(1):32–37.
Greer MA (See Sato N).
Griffin JE. Review: Hypothyroidism in the Elderly. 299(5):334–345.
Gyorkey F (See Musher DM).
Helfer EL, Miller JL, Rose LI. Cost Effectiveness of Routine Gonadotropin and Androgen Measurements in Hirsute Women. 299(2):94–97.
Henderson GI (See Schenker S).
Herbst JJ (See Jain SK).
Hescock H (See Balducci L).
Hillis LD (See Flores ED).
Hla-Yee-Yee (See Shirley DG).
Hojnacki J (See Doyle K).
Hui SL (See Murray MD).
Insel JM, Mookherjee S, Smulyan H, Warner RA. Use of Hepatic Vein Catheterization in the Evaluation of Patients with Anasarca. 299(4): 245–249.
Isola L (See Greenstein RJ).
Iwasaki T (See Kawashima S).
Jackson MW (See Fincher R-ME).
Jain SK, Ross JD, Duett J, Herbst JJ. Low Plasma Prealbumin and Carotenoid Levels in Sickle Cell Disease Patients. 299(1):13–15.
Jensen WA (See Kirsch CM).
Johnson RF (See Schenker S).
Kaul S. Review: Assessment of Myocardial Perfusion with Contrast Two-Dimensional Echocardiography. 299(2):113–130.
Kawashima S, Ueno M, Kondo T, Yamamoto J, Iwasaki T. Case Report: Marked Cardiac Involvement in Limb-Girdle Muscular Dystrophy. 299(6): 411–414.
Kiefe C (See Lichtenstein M).
Kim EL, Ching DL, Pien FD. Bacterial Endocarditis at a Small Community Hospital. 299(2):87–93.
King TS (See Schenker S).
Kirsch CM, Azzi RL, Yenokida GG, Jensen WA. Analysis of Induced Sputum in the Diagnosis of *Pneumocystis carinii* Pneumonia. 299(6):386–391.
Koide H (See Tomino Y).
Kokko JP. SSCI Presidential Address: Metabolic and Social Consequences of Cocaine Abuse. 299(6):361–365.
Kondo T (See Kawashima S).
Lahart C (See Musher DM).

Lam M (See Fried T).
Lane TJ, Matthews DA, Manu P. Low Yield of Physical Examinations and Laboratory Investigations of Patients with Chronic Fatigue. 299(5): 313–318.
Lange RA (See Flores ED).
Lawton WJ (See Fried T).
Leffler CW (See White RP).
Levy JR, Belsky M. Down-Regulated Insulin Receptors in HepG2 Cells Have an Altered Intracellular Itinerary. 299(5): 302–308.
Lichtenstein M, Kiefe C. Incorporating Severity of Illness into Estimates of Likelihood Ratios. 299(1):38–41.
Lieberman J, Schwartzman MN. Assay of a Urinary CF-Lectin Factor as a Second Diagnostic Test for Cystic Fibrosis. 299(2):103–106.
Loverde M (See Gerber JG).
Lower EE, Baughman RP. The Use of Low Dose Methotrexate in Refractory Sarcoidosis. 299(3):153–157.
Luft FC (See Fried T).
McCullough A (See Fried T).
McCully KS. Atherosclerosis, Serum Cholesterol and the Homocysteine Theory: A Study of 194 Consecutive Autopsies. 299(4):217–221.
McDonald CJ (See Murray MD).
McMurray RW, Bradshear RW, Steele RW, Pilkington NS. Effect of Prolonged Modified Fasting in Obese Persons on In Vitro Markers of Immunity: Lymphocyte Function and Serum Effects on Normal Neutrophils. 299(6): 379–385.
McPherson E, Perlin E, Finke H, Castro O, Pittman J. Patient-Controlled Analgesia in Patients with Sickle Cell Vaso-Occlusive Crisis. 299(1): 10–12.
Martinez-Maldonado M (See Fried T).
Mendonca-Calaca WDe (See Carella MJ).
Miller JL (See Helfer EL).
Mookherjee S (See Insel JM).
Mosqueda-Garcia R. Topics in Clinical Pharmacology: Guanfacine: A Second Generation α_2-Adrenergic Blocker. 299(1):73–76.
Mundy GR. SSCI Founder's Medal: Presentation to Dr. Jay H. Stein. 299(6): 372–373.
Murray, RH (See Carella MJ).
Murray M, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated Renal Impairment in a Large General Internal Medicine Practice. 299(4):222–229.
Musher DM, Watson DA, Nickeson D, Gyorkey F, Lahart C, Rossen RD. The Effect of HIV Infection on Phagocytosis and Killing of *Staphylococcus aureus* by Human Pulmonary Alveolar Macrophages. 299(3):158–163.
Nell LJ (See Ellerhorst JA).
Nickeson D (See Musher DM).
Nies AS (See Gerber JG).
Ober KP. Case Report: Postpartum Hypopituitarism with Preservation of the Pituitary-Ovarian Axis. 299(4):257–259.
Oelsner D (See Clifton GG).
O'Neil CE. Review: Mechanisms of Occupational Airways Diseases Induced by Exposure to Organic and Inorganic Chemicals. 299(4):265–275.
Parker LN (See Wu S-Y).
Parker M (See Balducci L).
Pearce CJ (See Clifton GG).
Pearl SG (See Philbrick JT).
Perlin E (See McPherson E).
Petrillo A (See Fried T).
Philbrick JT, Connelly JE, Corbett EC Jr, Ropka ME, Pearl SG, Reid RA, Fedson DS. Restoring Balance to Internal Medicine Training: The Case for the Teaching Office Practice. 299(1): 43–49.
Pien FD (See Kim EL).
Pilkington NS (See McMurray RW).
Pittman J (See McPherson E).
Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. Ancrod Causes Rapid Thrombolysis in Patients with Acute Stroke. 299(5): 319–325.
Reid RA (See Philbrick JT).
Rodu B. Molecular Biology in Medicine: The Polymerase Chain Reaction: The Revolution Within. 299(3):210–216.
Ropka ME (See Philbrick JT).
Rose LI (See Helfer EL).
Rossen RD (See Musher DM).
Ross JD (See Jain SK).
Rubin CD. Southwestern Internal Medicine Conference: Urinary Incontinence in the Elderly. 299(2):131–147.
Sakai H (See Tomino Y).
Sands JM (See Tumlin JA).
Sato N, Wing X, Greer MA. Hyposmolarity Stimulates Myeloperoxidase Exocytosis from Human Polymorphonuclear Leukocytes. 299(5):309–312.
Savin VJ (See Weigmann TB).
Schenken RS (See Schenker S).
Schenker S, Johnson RF, King TS, Schenken RS, Henderson GI. Azidothymidine (Zidovudine) Transport by the Human Placenta. 299(1): 16–20.
Schwartzman MN (See Lieberman J).
Schwarz HP, Tschaeppeler H, Zuppinger K. Case Report: Unsustained Central Sexual Precocity in Four Girls. 299(4):260–264.
Sexton W (See Balducci L).
Sharma R (See Weigmann TB).
Shear CL (See Berenson GS).
Shirley DG, Hla-Yee-Yee. The Influence of Posture on Renal Tubular Function in Man. 299(5):326–330.
Smulyan H (See Insel JM).
Someren A (See Tumlin JA).
Steele RW (See McMurray RW).
Tanaka S (See Tomino Y).
Tantranond P (See Balducci L).
Tierney WM (See Murray MD).
Tomino Y, Koide H, Yagame M, Sakai H, Tanaka S. Preliminary Study on Specificity of IgA Released from Lymphocytes by EB Virus Transformation in Patients with IgA Nephropathy. 299(6):374–378.
Toto RD. Review: Acute Tubulointerstitial Nephritis. 299(6):392–410.
Trochtenberg DS, Dessypris EN. Case Report: Reversible Hepatomegaly and Diabetes Mellitus in an Adult with Disseminated Histiocytosis X. 299(3):179–184.
Tschaeppeler H (See Schwarz HP).
Tumlin JA, Sands JM, Someren A. Hemolytic-Uremic Syndrome Following "Crack" Cocaine Inhalation. 299(6): 366–371.
Ueno M (See Kawashima S).
Voors AW (See Berenson GS).
Wall BM (See Williams HH).
Wallin JD (See Clifton GG).
Wang X (See Sato N).
Warner RA (See Insel JM).
Watson DA (See Musher DM).
Watts NB, Digirolamo M. Carbohydrate Tolerance Improves with Fasting in Obese Subjects with Noninsulin-Dependent (Type II) Diabetes. 299(4):250–256.
Webber LS (See Berenson GS).
Weigmann TB, Sharma R, Diederich DA, Savin VJ. In Vitro Effects of Cyclosporine on Glomerular Filtration. 299(3):149–152.
Weitberg AB. Hydroxy- and Hydroperoxy-6,8,11,14-Eicosatetraenoic Acids Induce Sister Chromatid Exchanges in Cultured Mammalian Cells. 299(1): 50–53.
White RP, Leffler CW, Bada HS. Eicosanoid Levels in CSF of Premature Infants with Posthemorrhagic Hydrocephalus. 299(4):230–235.
Williams HH, Wall BM, Cooke CR. Case Report: Reversible Nephrotic Range Proteinuria and Renal Failure in Atheroembolic Renal Disease. 299(1): 58–61.
Wilson MA. Southwestern Internal Medical Conference: Treatment of Obesity. 299(1):62–68.
Wright C (See Wu S-Y).
Wu S-Y, Wright C, Parker LN, Florsheim W. Induction of Type II T_4-5'-Monodeiodinase Activity in Brown Adipose Tissue in Fasted Mice. 299(1): 21–25.
Yagame M (See Tomino Y).
Yamamoto J (See Kawashima S).
Yangco BG (See Greene JN).
Yenokida GG (See Kirsch CM).
Zuppinger K (See Schwarz HP).

TITLES

Analysis of Induced Sputum in the Diagnosis of *Pneumocystis carinii* Pneumonia. Kirsch CM, Azzi RL, Yenokida GG, Jensen WA. 299(6):386–391.
Ancrod Causes Rapid Thrombolysis in Patients with Acute Stroke. Pollak VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. 299(5):319–325.

Assay of a Urinary CF-Lectin Factor as a Second Diagnostic Test for Cystic Fibrosis. Lieberman J, Schwartzman MN. 299(2):103–106.

Atherosclerosis, Serum Cholesterol and the Homocysteine Theory: A Study of 194 Consecutive Autopsies. McCully KS. 299(4):217–221.

Azidothymidine (Zidovudine) Transport by the Human Placenta. Schenker S, Johnson RF, King TS, Schenken RS, Henderson GI. 299(1): 16–20.

Bacterial Endocarditis at a Small Community Hospital. Kim EL, Ching DL, Pien FD. 299(2):87–93.

Carbohydrate Tolerance Improves with Fasting in Obese Subjects with Noninsulin-Dependent (Type II) Diabetes. Watts NB, Digirolamo M. 299(4):250–256.

Clinical Assessment of Central Venous Pressure in the Critically Ill. Cook DJ. 299(3):175–178.

Combined Low-Dose Medication and Primary Intervention Over a 30-Month Period for Sustained High Blood Pressure in Childhood. Berenson GS, Shear CL, Chiang YK, Webber LS, Voors, AW. 299(2):79–86.

Cost Effectiveness of Routine Gonadotropin and Androgen Measurements in Hirsute Women. Helfer EL, Miller JL, Rose LI. 299(2):94–97.

Differential Cholecystokinin Gene Expression in Brain and Gut of the Fasted rat. Greenstein RJ, Isola L, Gordon J. 299(1):32–37.

Down-Regulated Insulin Receptors in HepG2 Cells Have an Altered Intracellular Itinerary. Levy JR, Belsky M. 299(5):302–308.

Effect of HIV Infection on Phagocytosis and Killing of *Staphylococcus aureus* by Human Pulmonary Alveolar Macrophages. Musher DM, Watson DA, Nickeson D, Gyorkey F, Lahart C, Rossen RD. 299(3):158–163.

Effect of Prolonged Modified Fasting in Obese Persons on In Vitro Markers of Immunity: Lymphocyte Function and Serum Effects on Normal Neutrophils. McMurray RW, Bradshear RW, Steele RW, Pilkington NS. 299(6):379–385.

Effects of Mercuric Chloride on Calmodulin-Mediated Ca^{+2} Transport in Rat Brain. Cliftin GG, Oelsner D, Anderson CR, Pearce CJ, Wallin JD. 299(1):26–31.

Eicosanoid Levels in CSF of Premature Infants with Posthemorrhagic Hydrocephalus. White RP, Leffler CW, Bada HS. 299(4):230–235.

Ethanol-Induced Alterations in Erythrocyte Membrane Phospholipid Composition. Doyle K, Hojnacki J, Cluette-Brown J. 299(2):98–102.

Heterogeneity of TSH Receptor-binding Antibodies in Hashimoto's Thyroiditis and Graves' Disease. De Bruin TWA, Braverman LE, Brown RS. 299(5).291–297.

Hydralazine Does Not Stimulate Prostacyclin Biosynthesis in Hypertensive Patients. Gerber JG, Beckmann ML, Loverde M, Byyny RL, Nies AS. 299(3): 170–174.

Hydroxy- and Hydroperoxy-6,8,11, 14-Eicosatetraenoic Acids Induce Sister Chromatid Exchanges in Cultured Mammalian Cells. Weitberg AB. 299(1): 50–53.

Hyperkalemia in Diabetic ketoacidosis. Fulop M. 299(3):164–169.

Hyposmolarity Stimulates Myeloperoxidase Exocytosis from Human Polymorphonuclear Leukocytes. Sato N, Wing X, Greer MA. 299(5):309–312.

Ibuprofen-associated Renal Impairment in a Large General Internal Medicine Practice. Murray M, Brater DC, Tierney WM, Hui SL, McDonald CJ. 299(4):222–229.

Incorporating Severity of Illness into Estimates of Likelihood Ratios. Lichtenstein M, Kiefe C. 299(1):38–41.

Induction of Type II T_4-5′-Monodeiodinase Activity in Brown Adipose Tissue in Fasted Mice. Wu S-Y, Wright C, Parker LN, Florsheim W. 299(1):21- 25.

Influence of Posture on Renal Tubular Function in Man. Shirley DG, Hla-Yee- Yee. 299(5):326–330.

In Vitro Effects of Cyclosporine on Glomerular Filtration. Weigmann TB, Sharma R, Diederich DA, Savin VJ. 299(3):149–152.

Low Plasma Prealbumin and Carotenoid Levels in Sickle Cell Disease Patients. Jain SK, Ross JD, Duett J, Herbst JJ. 299(1):13–15.

Low Yield of Physical Examinations and laboratory Investigations of Patients with Chronic Fatigue. Lane TJ, Matthews DA, Manu P. 299(5): 313–318.

Patient-Controlled Analgesia in Patients with Sickle Cell Vaso-Occlusive Crisis. McPherson E, Perlin E, Finke H, Castro O, Pittman J. 299(1): 10–12.

Preliminary Study on Specificity of IgA Released from Lymphocytes by EB Virus Transformation in Patients with IgA Nephropathy. Tomino Y, Koide H, Yagame M, Sakai H, Tanaka S. 299(6):374–378.

Presidential Address of the SSCI: Metabolic and Social Consequences of Cocaine Abuse. 299(6):361–365.

Protamine Antibody Production in Diabetic Subjects Treated with NPH Insulin. Ellerhorst JA, Comstock JP, Nell LJ. 299(5):298–301.

Renal and Hemodynamic Effects of Atrial Natriuretic Peptide in Patients with Cirrhosis. Fried T, Aronoff GR, Benabe JE, Brunner HR, DiBona GF, Fleischhauer T, Lam M, Lawton WJ, Luft FC, Martinez-Maldonado M, McCullough A, Petrillo A. 299(1):2–9.

Restoring Balance to Internal Medicine Training: The Case for the Teaching Office Practice. Philbrick JT, Connelly JE, Corbett EC Jr, Ropka ME, Pearl SG, Reid RA, Fedson DS. 299(1):43–49.

Side Effects of β-Blocker Treatments as Related to the Central Nervous System. Dahlöf C, Dimenäs E. 299(4): 236–244.

SSCI Founder's Medal: Presentation to Dr. Jay H. Stein. 299(6):372–373.

Use of Hepatic Vein Catheterization in the Evaluation of Patients with Anasarca. Insel JM, Mookherjee S, Smulyan H, Warner RA. 299(4): 245–249.

Use of Low Dose Methotrexate in Refractory Sarcoidosis. Lower EE, Baughman RP. 299(3):153–157.

Case Reports

Chromomycosis in a Steroid-Dependent Patient with Chronic Obstructive Pulmonary Disease. Greene JN, Foulis PR, Yangco BG. 299(1):54–57.

***Citrobacter Freundii*: A Newly Reported Cause of Pyomyositis**. Fincher R-ME, Jackson MW, Fischer AQ. 299(5):331–333.

Diffuse Pulmonary Tumor Microemboli from Prostatic Carcinoma with an Associated Fibrous Histiocytic Sarcoma. Carella MJ, Murray RH, Mendonca-Calaca WDe. 299(2):107–112.

Special Feature: Hemolytic-Uremic Syndrome Following "Crack" Cocaine Inhalation. Tumlin JA, Sands JM, Someren A. 299(6):366–371.

Marked Cardiac Involvement in Limb-Girdle Muscular Dystrophy. Kawashima S, Ueno M, Kondo T, Yamamoto J, Iwasaki T. 299(6):411–414.

Postpartum Hypopituitarism with Preservation of the Pituitary-Ovarian Axis. Ober KP. 299(4):257–259.

Reversible Hepatomegaly and Diabetes Mellitus in an Adult with Disseminated Histiocytosis X. Trochtenberg DS, Dessypris EN. 299(3): 179–184.

Reversible Nephrotic Range Proteinuria and Renal Failure in Atheroembolic Renal Disease. Williams HH, Wall BM, Cooke CR. 299(1): 58–61.

Unsustained Central Sexual Precocity in Four Girls. Schwarz HP, Tschaeppeler H, Zuppinger K. 299(4):260–264.

Reviews

Acute Tubulointerstitial Nephritis. Toto RD. 299(6):392–410.

Assessment of Myocardial Perfusion with Contrast Two-Dimensional Echocardiography. Kaul S. 299(2): 113–130.

Hypothyroidism in the Elderly. Griffin JE. 299(5):334–345.
Mechanisms of Occupational Airways Diseases Induced by Exposure to Organic and Inorganic Chemicals. O'Neil CE. 299(4):265–275.
Systemic Management of Prostate Cancer. Balducci L, Parker M, Hescock H, Tantranond P, Sexton W. 299(3):185–192.

Southwestern Internal Medicine Conference
Clinical Features, Pathogenic Mechanisms, and New Developments in the Treatment of Systemic Sclerosis. Geppert T. 299(3):193–209.
Hepatitis C. Cuthbert JA. 299(5):346–355.
Prevention of Congestive Heart Failure: Left Ventricular Dilation and its Management. Firth BG, Dunnmon PM. 299(4):276–290.
Therapy of Acute Myocardial Infarction in the 1990s. Flores ED, Lange RA, Cigarroa RG, Hillis LD. 299(6): 415–424.
Treatment of Obesity. Wilson MA. 299(1):62–68.
Urinary Incontinence in the Elderly. Rubin CD. 299(2):131–147.

Molecular Biology in Medicine
DNA Isolation and Southern Analysis: A Clinician's View. Borst M, Miller M. 299(5):356–360.
Gene Mapping and Cystic Fibrosis. Barker PE. 299(1):69–72.
Polymerase Chain Reaction: The Revolution Within. Rodu B. 299(3): 210–216.

Topics in Clinical Pharmacology
Guanfacine: A Second Generation α_2-Adrenergic Blocker. Mosqueda-Garcia R. 299(1):73–76.

Key Indexing Terms
Acute myocardial infarction 299(6):415–424
Acute renal failure 299(4):222–229
Acute renal failure 299(6):366–371
Acute renal failure 299(6):392–410
Acute stroke 299(5):319–325
Adenocarcinoma 299(3):185–192
α_2-Adrenergic blocker 299(1):73–76
Adults 299(3):179–184
Aging 299(5):334–345
AIDS 299(6):386–391
Aminoglycosides 299(2):103–106
Ancrod 299(5):319–325
Androgens 299(2):94–97
ANP 299(1):2–9
Anti-inflammatory agents 299(4):222–229
Ascites 299(4):245–249
Atheroembolism 299(1):58–61
Atherosclerosis 299(4):217–221
Atrial natriuretic peptides 299(1):2–9
Azidothymidine 299(1):16–20
Bacterial endocarditis 299(2):87–93
β-Blockade 299(4):236–244
Brain 299(1):26–31
Brain 299(1):32–37
Brown fat 299(1):21–25
Calmodulin 299(1):26–31
Cardiac enzymes 299(6):411–414
Cardiovascular disease 299(2):79–86
Carotenoids 299(1):13–15
CCK 299(1):32–37
Cell-mediated immunity 299(6):379–385
Central nervous system 299(4):236–244
Central venous pressure 299(3):175–178
Cerebrospinal fluid 299(4):230–235
Chemotherapy 299(3):185–192
Cholecystokinin 299(1):32–37
Chronic fatigue 299(5):313–318
Cirrhosis 299(1):2–9
Citrobacter Freundii 299(5):331–333
Clinical disagreement 299(3):175–178
Clinical examination 299(3):175–178
Cocaine 299(6):366–371
Cocaine abuse 299(6):361–365
Combined androgen blockade 299(3):185 192
Community hospital infection 299(2):87 93
Compensatory hypertrophy 299(4):276 290
Complications 299(3):179–184
Computers 299(4):222–229
Congestive heart failure 299(4):276–290
Control trial 299(5):319–325
Cor pulmonale 299(2):107–112
Cortical necrosis 299(6):366–371
C-peptide 299(4):250–256
Curriculum 299(1):43–49
Cutaneous chromomycosis 299(1):54–57
Cyclosporine 299(3):149–152
Cystic fibrosis 299(1):69–72
Cystic fibrosis 299(2):103–106
Diabetes mellitus 299(3):179–184
Diabetes mellitus 299(4):217–221
Diabetes mellitus 299(4):250–256
Diabetes mellitus 299(5):298–301
Diabetic ketoacidosis 299(3):164–169
Diagnostic test 299(1):38–41
Diet, reducing 299(1):62–68
Dilated cardiomyopathy 299(6):411–414
2,3-Dinor-6-keto-prostaglandin $F_{1\alpha}$ 299(3) 170–174
DNA isolation 299(5):356–360
Downregulation 299(1):32–37
Drugs 299(6):392–410
EB virus 299(6):374–378
Education, graduate 299(1):43–49
Education, medical 299(1):43–49
Eicosanoids 299(4):230–235
Elderly 299(2):131–147
Energy metabolism 299(1):62–68
Epidemiology 299(4):222–229
Erythrocyte membranes 299(2):98–102
Ethanol 299(2):98–102
Exercise 299(1):62–68
Fasting 299(1):21–25
Fasting 299(4):250–256
Fasting 299(6):379–385
Fatty acids 299(2):98–102
Fibrinolysis 299(5):319–325
FRTL-5 cells 299(5) 291–297
Fungal infection 299(1):54–57
Gene expression 299(1):32–37
Gene mapping 299(1):69–72
Genetic linkage 299(1):69–72
Girls 299(4):260–264
Glomerular filtration rate 299(3):149–152
Glomerular function 299(3):149–152
Glomerulosclerosis 299(1):58–61
Glomerulus 299(3):149–152
Glucose tolerance 299(4):250–256
Gonadotropins 299(2):94–97
Guanfacine 299(1):73–76
Gut 299(1):32–37
Heart catheterization 299(4):245–249
Hemodynamics 299(1):2–9
Hemolytic uremic syndrome 299(6):366–371
Hemorrhagic hydrocephalus 299(4):230–235
Hepatic veins 299(4):245–249
Hepatitis C 299(5):346–355
Hepatomegaly 299(3):179–184
HepG2 cells 299(5):302–308
Hirsutism 299(2):94–97
Histiocytoma, fibrous 299(2):107–112
Histiocytosis X 299(3):179–184
HIV infection 299(3):158–163
Homocysteine theory 299(4):217–221
Hormone 299(1):32–37
Hormone therapy 299(3):185–192
Human polymorphonuclear leukocytes 299(5):309–312
Humans 299(1):2–9
Hydralazine 299(3):170–174
Hyperkalemic hyperchloremic metabolic acidosis 299(6):392–410
Hypertension 299(2):79–86
Hypertension, portal 299(4):245–249
Hypertension, pulmonary 299(2):107–112
Hypopituitarism 299(4):257–259
Hyposmolarity 299(5):309–312
Hypothyroidism 299(5):334–345
Ibuprofen 299(4):222–229
IgA binding 299(6):374–378
IgA nephropathy 299(6):374–378
Immune mechanisms 299(4):265–275
Immunity 299(6):379–385
Immunoprecipitation assay 299(5) 291–297
Immunosuppressed host 299(1):54–57
Indomethacin 299(3):170–174
Induced sputum 299(6):386–391
Infarct expansion 299(4):276–290
Inorganic chemicals 299(4):265–275
Insulin 299(4):250–256
Insulin antibodies 299(5):298–301
Insulin receptors 299(5):302–308
Insulin therapy 299(5):298–301
Intraaortic echocardiography 299(2):113–130
In vitro markers of immunity 299(6):379–385
Irritant gases 299(4):265–275
Ketoacidosis 299(3):164–169
Ketoacidosis 299(3):179–184
Kidney 299(3):149–152
Kidney failure 299(4):222–229
Laboratory investigations 299(5):313–318
Lactate 299(4):250–256
Lectin 299(2):103–106
Left ventricular dilation 299(4):276–290
Likelihood ratios 299(1):38–41
Limb-girdle muscular dystrophy 299(6): 411–414
Lipid peroxidation 299(1):50–53
Lipophilicity 299(4):236–244

Lithium clearance 299(5):326–330
Liver 299(1):21–25
Liver cirrhosis 299(4):245–249
Liver disease 299(3):179–184
Low molecular weight chemicals 299(4): 265–275
Lymphocyte function 299(6):379–385
Lymphocytes 299(6):374–378
Mass spectrometry 299(3):170–174
Meperidine 299(1):10–12
Mercuric chloride 299(1):26–31
Methotrexate 299(3):153–157
Mice 299(1):21–25
Microangiopathic anemia 299(6):366–371
Microsomal antibody 299(5) 291–297.
Myeloperoxidase exocytosis 299(5):309–312
Myocardial contrast echocardiography 299(2):113–130
Neoplasm circulating cells 299(2):107–112
Neoplasm metastasis 299(2):107–112
Neoplasms, multiple primary 299(2):107–112
Nephritis 299(6):392–410
Neutrophils 299(6):379–385
Noninsulin-dependent diabetes mellitus 299(4):250–256
Non-specific bronchial hyperreactivity 299(4):265–275
Non-steroidal anti-inflammatory agents 299(4):222–229
NPH insulin 299(5):298–301
Obesity 299(1):62–68
Obesity 299(4):250–256
Obesity 299(6):379–385
Occupational asthma 299(4):265–275
Occupational lung diseases 299(4):265–275
Organic chemicals 299(4):265–275
Ovarian function 299(4):257–259
Oxygen radicals 299(1):50–53
Patient-controlled analgesia 299(1):10–12
Pediatrics 299(2):79–86
Phagocytosis 299(3):158–163
Phospholipids 299(2):98–102
Physical examinations 299(5):313–318
Placenta 299(1):16–20
Pneumocystis carinii pneumonia 299(6): 386–391
Polymerase chain reaction 299(3):210–216
Polymorphonuclear leukocyte function 299(6):379–385
Posture 299(5):326–330
Potassium 299(3):164–169
Prealbumin 299(1):13–15
Precocious puberty 299(4):260–264
Prednisone 299(3):153–157
Premature thelarche 299(4):260–264
Prognosis 299(3):179–184
Prolactin 299(2):94–97
Prostacyclin biosynthesis 299(3):170–174
Prostate 299(3):185–192
Prostatic neoplasms 299(2):107–112
Protamine immunity 299(5):298–301
Protein-sparing modified fasting 299(6): 379–385
Proteinuria 299(1):58–61
Proximal tubule 299(5):326–330
Pulmonary macrophages 299(3):158–163
Pyomyositis 299(5):331–333
Receptor epitopes 299(5) 291–297
Renal disease 299(1):58–61
Review 299(3):185–192
Sarcoidosis 299(3):153–157
Sarcoma 299(2):107–112
Sclerosis 299(3):193–209
Sensitivity 299(1):38–42
Sensitization 299(4):265–275
Serum cholesterol 299(4):217–221
Serum potassium 299(3):164–169
Sickle cell disease 299(1):13–15
Sickle cell vaso-occlusive crisis 299(1):10–12
Side effects 299(4):236–244
Sister chromatid exchanges 299(1):50–53
Sodium 299(5):326–330
Southern analysis 299(5):356–360
Specificity 299(1):38–42
Squirrel monkeys 299(2):98–102
Starvation ketosis 299(6):379–385
Subjective symptoms 299(4):236–244
Sweat test 299(2):103–106
Systemic sclerosis 299(3):193–209
Systemic treatment 299(3):185–192
T_4-deiodinase 299(1):21–25
Therapy 299(3):179–184
Thyroid function tests 299(5):334–345
Thyroid stimulating antibody 299(5) 291–297
Tissue plasminogen activator 299(5):319–325
Transient sexual precocity 299(4):260–264
TSH-binding inhibitor immunoglobulins 299(5) 291–297.
Tubulointerstitial nephritis 299(6):392–410
Unsustained puberty 299(4):260–264
Urinary incontinence 299(2):131–147
Urine 299(2):103–106 299(2) 131–147
Water diuresis 299(5):326–330
Weight loss 299(1):62–68
Zidovudine 299(1):16–20